Chemotherapy regimens EGFR TKI regimensa
Study ALK+ (N) Regimen/ Line of treatment Efficacy ALK+ (N) Response rate Efficacy
Studies with no control or adjustment for confounding factors
Shaw et al. [15] 12 ALK+ metastatic cases evaluable for chemo 1st line platinum-based chemo Median TTP reported as “in the range of 8–10 months” across ALK+, EGFR mu, and WT/WT 10 ALK+
stage IV 		• 0% in ALK+
• 70% in EGFR mu
• 13% in WT/WT
 Median TTP:
• 5 months in ALK+
• 16 months in EGFR mu
• 6 months in WT/WT
Koh et al. [22] 32 ALK+ advanced adeno cases 1st line platinum-based doublet chemo Median PFS:
• 6.2 months in ALK+
• 5.4 months in EGFR mu
• 7.3 months in WT/WT
16 ALK+ advanced adeno • 0% in ALK+
• 50% in EGFR mu
• 6.9% in WT/WT
Median PFS:
• 4.3 weeks in ALK+
• 19.6 weeks in EGFR mu
• 6.0 weeks in WT/WT
Wang et al. [17] 4 ALK+ stage IV 1st and 2nd line platinum-based doublet chemo Median PFS:c
• 8.3 months in ALK+
• 4.1 months in EGFR mu
• 4.9 months in WT/WT
9 ALK+
stage IV 		• 33.3% in ALK+
• 46.9% in EGFR mu
• 16.3% in WT/WT
 Median PFS:
• 2.1 months in ALK+
• 8.8 months in EGFR mu
• 2.2 months in WT/WT
Takeda et al.  [16] 18 ALK+
advanced non squamous cases 		1st line platinum-based chemo Median PFS:c
• 6.5 months in ALK+
• 6.0 months in EGFR mu
• 4.3 months in WT/WT
Not studied
Studies with control or adjustment for confounding factors
 Lee et al. [6] 21 ALK+ matched to 34 EGFR mu and 37WT/WT cases all stage IIIb–IVd 1st line chemob Median PFS • 3.87 months in ALK+
• 4.93 months in EGFR mu
• 3.73 months in WT/WT
 10 ALK+ matched to 42 EGFR muand 27 WT/WTd • 0% in ALK+
• 80.9% in EGFR mu
• 14.8% in WT/WT
 Median PFS:
• 1.37 months in ALK+
• 9.80 months in EGFR mu
• 2.07 months in WT/WT
Kim et al. [5] 12 ALK+ never-smokers,
all stagese 		1st-line platinum-based chemo Median PFS:
• 5.0 months in ALK+
• 7.1 months in EGFR mu
• 7.2 months in KRAS mu
• 5.9 months in WT/WT/WT
 8 ALK+ never-smokers, all stagese • 0% in ALK+
• 65.5% in EGFR mu
• 0% in KRAS mu
• 10.3% in WT/WT/WT
 Median PFS:
• 1.6 months in ALK+
• 12.8 months in EGFR mu (p<0.001 vs.ALK+)
• 2.1 months in KRAS mu
• 6.3 months in WT/WT/WT (p=0.001 vs.ALK+)
a Line and treatment not stated; b all but 2 patients received platinum-based chemotherapy; c part of patients received pemetrexed treatment; d Matched on age at dx, sex, stage, smoking status; e Adjusted for age, sex, histology, PS, stage; mu, mutated; chemo, chemotherapy; adeno, adenocarcinoma; PFS, progression-free survival; TTP, time to progression
Table 2: Median PFS or TTP with Chemotherapy and EGFR TKI Regimens.